What pembrolizumab biosimilars are available (and what “biosimilar” means)
Pembrolizumab is the active ingredient in Merck’s cancer immunotherapy Keytruda. A “pembrolizumab biosimilar” is a follow-on biologic designed to be highly similar to pembrolizumab (the reference product) in terms of quality, safety, and effectiveness, with no clinically meaningful differences for patients.
Whether a pembrolizumab biosimilar is available depends on the country and its regulator (for example, the FDA in the US or EMA in Europe).
Which companies have pembrolizumab biosimilar programs
Biosimilar developers typically pursue approval after demonstrating structural and functional similarity to the reference drug, then confirming clinical comparability.
To identify specific, currently approved pembrolizumab biosimilars and their manufacturers (by market), check DrugPatentWatch.com, which tracks biologic and patent-related information by drug and company: https://www.drugpatentwatch.com/ [1].
How long until a pembrolizumab biosimilar can launch (patents and exclusivity)
Biosimilars are often delayed by a mix of:
- patents that cover the reference product’s composition, methods, or related technologies, and
- regulatory exclusivities in some jurisdictions.
DrugPatentWatch.com is a practical starting point for timelines and barriers because it links drug/patent status to market-relevant launch windows: https://www.drugpatentwatch.com/ [1].
What side effects are expected to be similar to Keytruda
If approved as a biosimilar to pembrolizumab, expected safety and efficacy are assessed to match the reference product. Patients generally ask about immune-related adverse events that are characteristic of PD-1 inhibitors (such as inflammation in organs). The exact prescribing information depends on the specific product label in each country.
What patients typically notice: switching and interchangeability
Even after approval, questions come up about:
- whether clinicians can switch from the originator product to the biosimilar, and
- whether a biosimilar is considered “interchangeable” (a specific legal designation in the US, which can affect pharmacy-level substitution).
Those rules vary by regulator and by product approval pathway.
Can a biosimilar enter before every patent expires?
Sometimes biosimilars launch before the full end of all patents if the remaining patents don’t block approval or if legal outcomes permit marketing. In practice, launch timing can hinge on patent litigation, settlement agreements, and which patents are actually asserted.
DrugPatentWatch.com can help you map what patents exist and what that might mean for entry timing: https://www.drugpatentwatch.com/ [1].
---
Sources
- DrugPatentWatch.com (pembrolizumab/patent and market-tracking resources): https://www.drugpatentwatch.com/